Estrella Immunopharma (ESLA) Competitors $1.06 -0.02 (-1.85%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. MIST, GNLX, FBRX, IKT, BHST, CHRS, ZURA, OTLK, ZNTL, and PLXShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Milestone Pharmaceuticals (MIST), Genelux (GNLX), Forte Biosciences (FBRX), Inhibikase Therapeutics (IKT), BioHarvest Sciences (BHST), Coherus Oncology (CHRS), Zura Bio (ZURA), Oncobiologics (OTLK), Zentalis Pharmaceuticals (ZNTL), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Its Competitors Milestone Pharmaceuticals Genelux Forte Biosciences Inhibikase Therapeutics BioHarvest Sciences Coherus Oncology Zura Bio Oncobiologics Zentalis Pharmaceuticals Protalix BioTherapeutics Estrella Immunopharma (NASDAQ:ESLA) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Which has stronger earnings and valuation, ESLA or MIST? Estrella Immunopharma has higher earnings, but lower revenue than Milestone Pharmaceuticals. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/AN/A-$0.26-4.04Milestone Pharmaceuticals$1M152.98-$41.52M-$0.84-2.14 Do analysts prefer ESLA or MIST? Estrella Immunopharma currently has a consensus target price of $16.00, indicating a potential upside of 1,423.81%. Milestone Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 177.78%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Estrella Immunopharma is more favorable than Milestone Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media prefer ESLA or MIST? In the previous week, Milestone Pharmaceuticals had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 1 mentions for Milestone Pharmaceuticals and 0 mentions for Estrella Immunopharma. Milestone Pharmaceuticals' average media sentiment score of 1.73 beat Estrella Immunopharma's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Estrella Immunopharma Neutral Milestone Pharmaceuticals Very Positive Is ESLA or MIST more profitable? Estrella Immunopharma's return on equity of -1,132.38% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -1,132.38% -358.54% Milestone Pharmaceuticals N/A -1,672.29%-83.09% Do institutionals and insiders believe in ESLA or MIST? 0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, ESLA or MIST? Estrella Immunopharma has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. SummaryMilestone Pharmaceuticals beats Estrella Immunopharma on 7 of the 12 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.03M$3.12B$5.77B$9.91BDividend YieldN/A2.29%6.71%4.52%P/E Ratio-4.0420.9775.5426.08Price / SalesN/A290.04480.4288.52Price / CashN/A44.9736.9659.01Price / BookN/A9.8611.446.09Net IncomeN/A-$53.47M$3.28B$266.14M7 Day PerformanceN/A2.89%0.84%0.28%1 Month Performance24.26%8.62%7.15%4.14%1 Year Performance-0.94%13.69%59.66%23.93% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma2.3166 of 5 stars$1.05-2.8%$16.00+1,423.8%+3.8%$40.03MN/A-4.04N/AGap DownMISTMilestone Pharmaceuticals1.6296 of 5 stars$1.69flat$5.00+195.9%+19.5%$143.64M$1M-2.0130Positive NewsGNLXGenelux1.1081 of 5 stars$3.79+1.3%$17.75+368.3%+46.8%$141.27M$10K-4.4110News CoverageFBRXForte Biosciences3.4141 of 5 stars$11.26-0.4%$68.00+503.9%+50.1%$140.68MN/A-0.695Positive NewsOptions VolumeIKTInhibikase Therapeutics1.6575 of 5 stars$1.84+4.5%$6.50+253.3%+26.7%$137.11MN/A-0.696Positive NewsBHSTBioHarvest SciencesN/A$9.00+8.4%$13.67+51.9%N/A$136.33M$30.19M-12.86N/APositive NewsGap DownHigh Trading VolumeCHRSCoherus Oncology4.0751 of 5 stars$1.13-3.4%$4.68+314.5%+0.0%$135.99M$266.96M0.73330News CoverageAnalyst UpgradeGap UpZURAZura Bio3.1327 of 5 stars$2.03-1.0%$14.00+589.7%-47.6%$133.29MN/A-2.903News CoverageOTLKOncobiologics2.0558 of 5 stars$2.70-9.1%$9.60+255.6%-87.9%$131.93MN/A-4.7420Options VolumeHigh Trading VolumeZNTLZentalis Pharmaceuticals2.5213 of 5 stars$1.85+1.6%$8.20+343.2%-45.5%$131.29M$67.43M-0.82160Positive NewsPLXProtalix BioTherapeutics3.1507 of 5 stars$1.62+1.3%$15.00+825.9%+57.4%$129.17M$61.95M-12.46200Positive News Related Companies and Tools Related Companies Milestone Pharmaceuticals Competitors Genelux Competitors Forte Biosciences Competitors Inhibikase Therapeutics Competitors BioHarvest Sciences Competitors Coherus Oncology Competitors Zura Bio Competitors Oncobiologics Competitors Zentalis Pharmaceuticals Competitors Protalix BioTherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
